SureTrader
Home > Boards > US Listed > Miscellaneous > Rigel Pharmaceuticals Inc. (RIGL)

7:40AM On The Wires (WIRES) :

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
surf1944 Member Profile
 
Followed By 424
Posts 22,006
Boards Moderated 2
Alias Born 09/11/06
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 2/4/2016 12:32:46 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 1/29/2016 5:04:02 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/28/2016 6:50:42 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/28/2016 6:50:12 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/28/2016 6:47:53 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/28/2016 6:47:24 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/28/2016 6:27:25 PM
Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP (FIT) "PR Newswire (US)" - 1/28/2016 7:30:00 AM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 1/27/2016 12:30:10 PM
Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisc... "PR Newswire (US)" - 1/7/2016 7:30:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/3/2015 4:33:26 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/3/2015 4:07:05 PM
Rigel Announces Third Quarter 2015 Financial Results "PR Newswire (US)" - 11/3/2015 4:05:00 PM
Rigel Announces Conference Call and Webcast to Report Third Quarter 2015 Financial Results "PR Newswire (US)" - 10/27/2015 7:30:00 AM
Rigel and Aclaris Therapeutics International Sign License Agreement for JAK Inhibitors to Treat Skin Disorders "PR Newswire (US)" - 9/9/2015 8:30:00 AM
Rigel Granted Orphan Drug Designation for Fostamatinib in ITP "PR Newswire (US)" - 9/8/2015 7:30:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 8/18/2015 4:55:48 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/18/2015 4:49:17 PM
Drugs - Generic Equities Coverage -- Oculus Innovative Sciences, Medicines, Supernus Pharma, Sophiris Bio, and Rigel Pharma "PR Newswire (US)" - 8/5/2015 9:35:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/4/2015 4:18:52 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/4/2015 4:10:06 PM
Rigel Announces Second Quarter 2015 Financial Results "PR Newswire (US)" - 8/4/2015 4:05:00 PM
Rigel Announces Conference Call and Webcast to Report Second Quarter 2015 Financial Results "PR Newswire (US)" - 7/28/2015 7:30:00 AM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 7/14/2015 6:01:27 AM
Confidential Treatment Order (ct Order) "Edgar (US Regulatory)" - 7/7/2015 3:48:29 PM
surf1944   Friday, 05/06/11 09:58:11 AM
Re: surf1944 post# 130
Post # of 334 
7:40AM On The Wires (WIRES) :

Rigel Pharmaceuticals, Inc. (RIGL) announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. Pfizer (PFE) is returning full rights to the R343 program as a result of its decision to exit the allergy and respiratory therapeutic area within R&D. Rigel is evaluating the details of R343's development to date and expects to design a Phase 2 clinical trial with R343 later this year.


surf's up......crikey



SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist